NIOX Group (LON:NIOX) Insider Sells 16,545 Shares of Stock

Key Points

• Insider Garry Watts sold 16,545 NIOX Group shares at an average price of 80 pence, for proceeds of £13,236.
• NIOX shares traded at 64.60 pence, up 0.3% on the day. The stock’s 12-month range is 53.84 to 80 pence, and its market capitalization is £271.88 million.
• The company reported quarterly EPS of 1.41 pence; analysts forecast full-year EPS of 1.17 pence on average.

NIOX Group Plc (LON:NIOX - Get Free Report) insider Garry Watts sold 16,545 shares of the business's stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of GBX 80, for a total value of £13,236.

NIOX Group Trading Up 0.3%

LON:NIOX traded up GBX 0.20 during midday trading on Wednesday, hitting GBX 64.60. 281,066 shares of the company traded hands, compared to its average volume of 902,221. The firm's fifty day moving average is GBX 67.34 and its 200-day moving average is GBX 63.13. NIOX Group Plc has a 12-month low of GBX 53.84 and a 12-month high of GBX 80. The firm has a market capitalization of £271.88 million, a P/E ratio of 39.63 and a beta of 0.92. The company has a current ratio of 4.60, a quick ratio of 1.94 and a debt-to-equity ratio of 1.06.

NIOX Group (LON:NIOX - Get Free Report) last posted its quarterly earnings data on Wednesday, September 30th. The company reported GBX 1.41 EPS for the quarter. NIOX Group had a net margin of 14.74% and a return on equity of 10.01%. On average, sell-side analysts predict that NIOX Group Plc will post 1.17 EPS for the current year.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.